Seelos Therapeutics Analyst Ratings
Seelos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 08/22/2023 | 555.52% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 555.52% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 555.52% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 1211.05% | Benchmark | $4 → $4 | Reiterates | Speculative Buy → Speculative Buy |
| 05/16/2023 | 555.52% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
| 05/15/2023 | 1211.05% | BTIG | $11 → $4 | Maintains | Buy |
| 03/30/2023 | 3505.38% | BTIG | → $11 | Maintains | Buy |
| 03/24/2023 | 1211.05% | Benchmark | $6 → $4 | Maintains | Buy |
| 02/13/2023 | 3833.14% | BTIG | $12 → $12 | Maintains | Buy |
| 04/28/2022 | 3833.14% | BTIG | → $12 | Maintains | Buy |
| 03/14/2022 | 1211.05% | B. Riley Securities | $6 → $4 | Maintains | Buy |
| 03/08/2022 | 883.28% | Cantor Fitzgerald | $5 → $3 | Maintains | Overweight |
| 09/27/2021 | 2522.09% | Roth Capital | $2.5 → $8 | Upgrades | Neutral → Buy |
| 08/10/2021 | 719.4% | Roth Capital | $4 → $2.5 | Maintains | Neutral |
| 07/01/2021 | 2522.09% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 06/01/2021 | 3177.61% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/30/2021 | 4816.42% | B. Riley Securities | → $15 | Initiates Coverage On | → Buy |
| 03/12/2021 | 4488.66% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/18/2019 | 555.52% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 11/14/2019 | — | Benchmark | Initiates Coverage On | → Speculative Buy | |
| 05/14/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 05/10/2019 | 1211.05% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/21/2023 | — | 坎託·菲茨傑拉德 | 降級 | 超重 → 中性 | |
| 08/22/2023 | 555.52% | 坎託·菲茨傑拉德 | → 2 美元 | 重申 | 超重 → 超重 |
| 08/15/2023 | 555.52% | 坎託·菲茨傑拉德 | → 2 美元 | 重申 | 超重 → 超重 |
| 06/23/2023 | 555.52% | 坎託·菲茨傑拉德 | → 2 美元 | 重申 | 超重 → 超重 |
| 06/23/2023 | 1211.05% | 基準 | 4 美元 → 4 美元 | 重申 | 投機性買入 → 投機性買入 |
| 05/16/2023 | 555.52% | 坎託·菲茨傑拉德 | 3 美元 → 2 美元 | 維護 | 超重 |
| 05/15/2023 | 1211.05% | BTIG | 11 美元 → 4 美元 | 維護 | 購買 |
| 03/30/2023 | 3505.38% | BTIG | → 11 美元 | 維護 | 購買 |
| 2023 年 3 月 24 日 | 1211.05% | 基準 | 6 美元 → 4 美元 | 維護 | 購買 |
| 02/13/2023 | 3833.14% | BTIG | 12 美元 → 12 美元 | 維護 | 購買 |
| 04/28/2022 | 3833.14% | BTIG | → 12 美元 | 維護 | 購買 |
| 03/14/2022 | 1211.05% | B. 萊利證券 | 6 美元 → 4 美元 | 維護 | 購買 |
| 03/08/2022 | 883.28% | 坎託·菲茨傑拉德 | 5 美元 → 3 美元 | 維護 | 超重 |
| 09/27/2021 | 2522.09% | 羅斯資本 | 2.5 美元 → 8 美元 | 升級 | 中性 → 買入 |
| 2021 年 10 月 8 日 | 719.4% | 羅斯資本 | 4 美元 → 2.5 美元 | 維護 | 中立 |
| 07/01/2021 | 2522.09% | 古根海姆 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/01/2021 | 3177.61% | 坎託·菲茨傑拉德 | → 10 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 03/30/2021 | 4816.42% | B. 萊利證券 | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 12 月 3 日 | 4488.66% | BTIG | → 14 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/18/2019 | 555.52% | HC Wainwright & Co. | 4 美元 → 2 美元 | 維護 | 購買 |
| 2019 年 11 月 14 日 | — | 基準 | 啓動覆蓋範圍開啓 | → 投機性買入 | |
| 2019 年 5 月 14 日 | — | 羅斯資本 | 啓動覆蓋範圍開啓 | → 購買 | |
| 2019 年 10 月 5 日 | 1211.05% | HC Wainwright & Co. | → 4 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Seelos Therapeutics (SEEL)?
Seelos Therapeutics（SEEL）的目標價格是多少？
The latest price target for Seelos Therapeutics (NASDAQ: SEEL) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $0.00 expecting SEEL to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年9月21日公佈了Seelos Therapeutics（納斯達克股票代碼：SEEL）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計SEEL將在12個月內跌至-100.00％（可能下跌-100.00％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Seelos Therapeutics (SEEL)?
分析師對Seelos Therapeutics（SEEL）的最新評級是多少？
The latest analyst rating for Seelos Therapeutics (NASDAQ: SEEL) was provided by Cantor Fitzgerald, and Seelos Therapeutics downgraded their neutral rating.
Seelos Therapeutics（納斯達克股票代碼：SEEL）的最新分析師評級由坎託·菲茨傑拉德提供，Seelos Therapeutics下調了中性評級。
When is the next analyst rating going to be posted or updated for Seelos Therapeutics (SEEL)?
Seelos Therapeutics（SEEL）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Seelos Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Seelos Therapeutics的最後一次評級是在2023年9月21日提交的，因此你應該預計下一個評級將在2024年9月21日左右公佈。
Is the Analyst Rating Seelos Therapeutics (SEEL) correct?
分析師對 Seelos Therapeutics (SEEL) 的評級正確嗎？
While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Seelos Therapeutics (SEEL) is trading at is $0.31, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Seelos Therapeutics（SEEL）評級已下調，目標股價爲0.00美元至0.00美元。Seelos Therapeutics（SEEL）目前的交易價格爲0.31美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。